Erik Vandendries

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

Hagop M. Kantarjian, Daniel J. DeAngelo, Matthias Stelljes et al. · New England Journal of Medicine · 2016 · 1.4K citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Accumulation of Tissue Factor into Developing Thrombi In Vivo Is Dependent upon Microparticle P-Selectin Glycoprotein Ligand 1 and Platelet P-Selectin

Shahrokh Falati, Qingde Liu, Peter L. Gross et al. · The Journal of Experimental Medicine · 2003 · 738 citations · Full text

Medicine, Molecular Biology, Pathobiology +17

Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study

Anjali S. Advani, Bertrand Coiffier, Myron S. Czuczman et al. · Journal of Clinical Oncology · 2010 · 334 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study

Hagop M. Kantarjian, Daniel J. DeAngelo, Matthias Stelljes et al. · Cancer · 2019 · 329 citations · Full text

Medicine, Oncology, Pharmacology +15

Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study

Hagop M. Kantarjian, Daniel J. DeAngelo, Anjali S. Advani et al. · The Lancet Haematology · 2017 · 212 citations

Medicine, Hematology, Pharmacology +17